35920-40-2

Usage

Uses

Given the limited information provided and the lack of specific applications mentioned in the materials, it is challenging to list the uses of (2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-cyclopentyl-3,4-dihydroxytetrahydrofuran-2-carboxamide (non-preferred name). However, based on its structural similarity to adenosine, we can hypothesize potential applications in the following areas:
Used in Pharmaceutical Industry:
(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-cyclopentyl-3,4-dihydroxytetrahydrofuran-2-carboxamide (non-preferred name) could be used as a pharmaceutical agent for the development of drugs targeting adenosine receptors or involved in adenosine-related physiological processes. Its potential application may include treatment of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders, as well as cardiovascular diseases, due to adenosine's role in regulating these systems.
Used in Research and Development:
In the field of scientific research, (2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-cyclopentyl-3,4-dihydroxytetrahydrofuran-2-carboxamide (non-preferred name) could be utilized as a research tool to study the mechanisms of action and signaling pathways related to adenosine and its receptors. It may also be employed in the development of new drugs or therapies targeting adenosine-mediated pathways.

Upstream product

• 39491-49-1 2',3'-O-isopropylideneadenosine-5'-carbonyl chloride 
• 1003-03-8 Cyclopentamine 
• 159647-45-7 (3aS,4S,6R,6aR)-6-(6-Amino-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid 4-nitro-phenyl ester 
• 19234-66-3 2',3'-isopropylideneadenosine-5'-carboxylic acid 
• 222527-44-8 (3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-N-cyclopentyl-2,2-dimethyl tetrahydrofuro[3,4-d][1,3]dioxole-4-carboxamide 

Relevant academic research and scientific papers

Optimization of adenosine 5′-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening

Structures of G protein-coupled receptors (GPCRs) have a proven utility in the discovery of new antagonists and inverse agonists modulating signaling of this important family of clinical targets. Applicability of active-state GPCR structures to virtual screening and rational optimization of agonists, however, remains to be assessed. In this study of adenosine 5′ derivatives, we evaluated the performance of an agonist-bound A2A adenosine receptor (AR) structure in retrieval of known agonists and then employed the structure to screen for new fragments optimally fitting the corresponding subpocket. Biochemical and functional assays demonstrate high affinity of new derivatives that include polar heterocycles. The binding models also explain modest selectivity gain for some substituents toward the closely related A 1AR subtype and the modified agonist efficacy of some of these ligands. The study suggests further applicability of in silico fragment screening to rational lead optimization in GPCRs.

Nucleosides and nucleotides. 200. Reinvestigation of 5′-N-ethylcarboxamidoadenosine derivatives: Structure-activity relationships for P3 purinoceptor-like proteins

The non-P1 and non-P2 muscle relaxant effect of ATP in rabbit thoracic aorta has recently been attributed to a putative P3 purinoceptor, which is activated by either adenosine or ATP. Since the physiological roles of this

5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors

Novel as well as known 5'-N-substituted carboxamidoadenosines were prepared via new routes that provided shorter reaction times and good yields. Binding affinities were determined for rat A1 and A(2A) receptors and human A3 receptors. EC50 values were determined for cyclic AMP production in CHO cells expressing human A(2B) receptors. On all receptor subtypes relatively small substituents on the carboxamido moiety were optimal. Selectivity for the A3 receptor was found for several analogues (1a, 1d, 1h, and 1k). On A1 receptors a number of compounds, but not 5'-N-ethylcarboxamidoadenosine (NECA, 1b), showed small GTP shifts, which could be indicative of lower intrinsic activities at the A1 receptor. At the A(2B) receptor, derivatives 1i-k with modified ethyl substituents had reduced activities compared to the A(2B) reference agonist NECA (1b). Thiocarboxamido derivatives (8b and 8c) displayed considerable although decreased A(2B) receptor activity. The X-ray structure determination of compound 8b was carried out. Due to intramolecular hydrogen bonding between the carboxamido NH and the purine N3 in the crystal structure, the ribose moiety of this compound is in a syn conformation. However, theoretical calculations support that NECA (1b), and less so 8b, can readily adopt both the syn and the anti conformation, therefore not excluding the proposed anti mode of binding to the receptor.

Modification of the 5' Position of Purine Nucleosides. 2. Synthesis and Some Cardiovascular Properties of Adenosine-5'-(N-substituted)carboxamides

We have shown previously that the esters of adenosine-5'-carboxylic acid (10) represent a new class of potent nontoxic coronary vasodilators.For example, the ethyl ester (12), which is active by an intraduodenal or intravenous route in dogs, causes a larg